Vitiligo
☆ I Stiftung Warentest-resultaten 2022 från Tyskland var konsumentnöjdheten med ModelDerm bara något lägre än med betalda telemedicinkonsultationer.
Vitiligo i fingrarna är svårare att behandla än andra områden. Bortsett från att vara kosmetiskt ful är vitiligo normalt och inte smittsamt. Inom dermatologi är den mest effektiva behandlingen fototerapi eller laserbehandling (excimer) 2-3 gånger i veckan i minst 1 år. Om du inte kan gå till sjukhuset ofta av ekonomiska skäl eller för att du är upptagen kan du prova en fototerapimaskin som är godkänd för hemmabruk.
Ögonlocksvitiligo
Vitiligo till hands
relevance score : -100.0%
ReferencesVitiligo är en vanlig hudsjukdom som ger vita fläckar på grund av förlust av melanocyter. Ny forskning visar att den är autoimmun. Även om den ofta betraktas som ett kosmetiskt problem kan den påverka det mentala välbefinnandet och det dagliga livet i stor utsträckning. År 2011 klassificerade experter en särskild form som heter segmental vitiligo separat från de andra typerna.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Patienter med aktiv vitiligo har flera terapialternativ, såsom systemiska glukokortikoider, fototerapi och systemiska immunsuppressiva medel. Patienter med stabil vitiligo kan få lindring av topikala kortikosteroider, topikala kalcineurinhämmare, fototerapi och transplantationsprocedurer. De senaste framstegen i förståelsen av vitiligos underliggande processer har lett till utvecklingen av riktade terapier. För närvarande är JAK‑hämmare de mest lovande; de ger god tolerabilitet och funktionella resultat, men det finns en risk för att latenta infektioner aktiveras samt för systemiska biverkningar som är vanliga med andra immunsuppressiva medel. Pågående forskning syftar till att identifiera nyckelcytokiner som är involverade i vitiligos utveckling (IFN‑γ, CXCL10, CXCR3, HSP70i, IL‑15, IL‑17/23, TNF). Blockering av dessa cytokiner har visat lovande resultat i djurmodeller och hos vissa patienter. Dessutom pågår studier av miRNA‑based therapeutics och adoptive Treg cell therapy.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Det finns inget känt botemedel mot vitiligo. För personer med ljus hy rekommenderas solskydd och kosmetik som vanligt. Andra behandlingsalternativ kan vara steroidkrämer eller fototerapi.
○ Behandling
#Phototherapy
#Excimer laser
#Tacrolimus ointment